Rectus-Intercostal Fascial Plane Block for Liver Transplantation Donors
Evaluation of Postoperative Analgesic Efficacy of Ultrasound-Guided Rectus-Intercostal Fascial Plane Block in Living Liver Donors
1 other identifier
interventional
64
1 country
1
Brief Summary
Postoperative pain control plays a crucial role in enhancing recovery and improving early mobilization in living liver donors. The rectus-intercostal fascial plane (RIFP) block is a novel ultrasound-guided regional anesthesia technique that provides anterior abdominal wall analgesia by targeting the intercostal nerves between the rectus abdominis and intercostal muscle fascia. This prospective, randomized controlled clinical study aims to evaluate the postoperative analgesic efficacy and opioid-sparing effects of the RIFP block compared with standard intravenous analgesia in living liver donors undergoing donor hepatectomy. Participants will be randomly assigned to two groups: Group 1 (RIFP Block): Patients receiving an ultrasound-guided rectus-intercostal fascial plane block using 20 mL of 0.25% bupivacaine at the end of surgery, in addition to standard IV PCA (morphine). Group 2 (Control): Patients receiving only standard IV PCA (morphine) without regional block.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 14, 2025
CompletedFirst Posted
Study publicly available on registry
November 18, 2025
CompletedStudy Start
First participant enrolled
December 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
ExpectedJanuary 8, 2026
November 1, 2025
4 months
November 14, 2025
January 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Morphine consumption
The amount of morphine required by the patient and given by the device will be recorded for the first 24 hours.
Postoperative 24 hours
Secondary Outcomes (3)
Postoperative visual analog scale scores
Postoperative 24 hours
Rescue analgesic drug consumption
postoperative 24 hours
Incidence of postoperative nausea and vomiting
postoperative 24 hours
Study Arms (2)
Rectus Intercostal Plane Block Group
ACTIVE COMPARATORRectus Intercostal Plane Block Group The patients in the Rectus Intercostal Plane Block group will receive a bilateral rectus intercostal plane block and patient-controlled analgesia (PCA) with morphine for postoperative analgesia.
Control Group
ACTIVE COMPARATORThe patients in the Control group will not receive any regional block and will receive PCA with morphine for postoperative analgesia.
Interventions
Rectus intercostal plane block will be administered bilaterally at the end of the surgery and after skin closure under ultrasound guidance
Ultrasound probe placement on the same region without needle insertion or local anesthetic injection to maintain blinding.
Eligibility Criteria
You may qualify if:
- Age between 18 and 75 years
- Patients with American Society of Anesthesiology (ASA) physical status I-II
- Patients scheduled for a living donor hepatectomy
You may not qualify if:
- Allergy to local anesthetics
- Coagulopathy
- Skin infection at the block area
- Advanced renal failure
- Chronic pain syndromes
- Alcohol or drug abuse
- Psychiatric disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
istinye University
Istanbul, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 14, 2025
First Posted
November 18, 2025
Study Start
December 22, 2025
Primary Completion
May 1, 2026
Study Completion (Estimated)
June 1, 2026
Last Updated
January 8, 2026
Record last verified: 2025-11